explore -WSS

explore

author：knowledge 2025-10-01 23:00:50 - browse：457

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Abbott's new heart device gets FDA advisory panel nod

leisure time

WSS

Meta's Zuckerberg and Chan on track to put $50 billion into science

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Physician subsidies by hospitals soar in wake of No Surprises Act

Cassava reveals details — and problems — with Alzheimer's study

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

knowledge

explore

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

Why Eli Lilly’s earnings didn’t quite live up to the hype

BioMarin wins approval for gene therapy to treat hemophilia A

Abbott's new heart device gets FDA advisory panel nod

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

CDC recommends rationing of RSV shot due to shortages

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: XBI biotech index, Akero Therapeutics

United colonoscopy coverage change 'may cost lives,' doctors say

ACIP vaccine advisory panel sees its vacancies filled

hotspot

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Resistance to opioid

Paying for Covid pills will soon shift to insurers

Telehealth options flood the market as retailers push virtual care

Cassava reveals details — and problems — with Alzheimer's study

Telehealth options flood the market as retailers push virtual care

knowledge

focus

leisure time

hotspot